Anteris Technologies (AVR) H2 2024 earnings summary

Executive summary

• Report covers the year ended December 31, 2024, prepared under US GAAP and audited by KPMG, with an emphasis of matter on going concern due to recurring losses and negative cash flows.

• The company completed a reorganization and IPO in December 2024, raising $80.1 million in net proceeds at $6.00 per share.

• Operations focus on R&D and clinical development of the DurAVRⓇ THV system for aortic stenosis, with limited revenue from legacy tissue products.

Financial highlights

• Net sales were $2.7 million, down 1% year-over-year, primarily from tissue product sales.

• Net loss after tax was $76.3 million, a 66% increase from $46.0 million in 2023, driven by higher R&D and SG&A expenses.

• R&D expenses rose 67% to $51.5 million, mainly due to pivotal trial preparations and manufacturing scale-up.

• SG&A expenses increased 62% to $28.2 million, reflecting IPO-related costs, stock option grants, legal provisions, and headcount growth.

• Cash and cash equivalents at year-end were $70.5 million, up from $21.1 million, primarily due to IPO proceeds.

• Accumulated deficit reached $276.4 million as of December 31, 2024.

• No dividends declared or paid.

Outlook and guidance

• The company expects to continue incurring substantial losses and negative cash flows until regulatory approval and commercialization of DurAVRⓇ THV.

• Additional capital will be required to fund ongoing R&D, clinical trials, and operational activities.

• Management believes it can raise further funds but acknowledges material uncertainties regarding going concern.